Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis

Pier Giorgio Puzzovio, Francesca Levi-Schaffer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


In the last years, the understanding of the pathologic mechanisms of asthma and atopic dermatitis, both characterized by allergic inflammation, has greatly improved. However, it is evident that both diseases present with high heterogeneity, which complicates the diagnosis and the therapeutic approach of the patients. Moreover, some of the currently available strategies to treat asthma and atopic dermatitis are still mostly controlling the symptoms, but not to lead towards full healing, thus having these two diseases labelled as unmet clinical needs by WHO. Therefore, the “one-size-fits-all” strategy is outdated for asthma and atopic dermatitis, and there is the need of better methods to clearly diagnose the disease and tailor the therapy according to the specific symptomatology. In this regard, the use of biomarkers has been advanced in order to characterize both diseases according to their clinical signs and to facilitate the subsequent treatment. Despite the advancements made in this regard, there is still need for better and more sensitive biomarkers and for less invasive sampling methodologies, with the aim to diagnose specifically each manifestation of asthma and atopic dermatitis and to provide the best treatment with the least suffering for the patients.

Original languageAmerican English
Article number747364
JournalFrontiers in Pharmacology
StatePublished - 30 Sep 2021

Bibliographical note

Publisher Copyright:
© Copyright © 2021 Puzzovio and Levi-Schaffer.


  • allergic inflammation
  • asthma
  • atopic dermatitis
  • biomarkers
  • eosinophils
  • neutrophils


Dive into the research topics of 'Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis'. Together they form a unique fingerprint.

Cite this